Andrx To Exit Brand Business, Focus On Generic Drugs

Law360, New York (January 5, 2005, 12:00 AM EST) -- Andrx Corp., a leading generic drug maker in the U.S., has vowed to exit its loss-making brand business and concentrate completely on generic drugs and the pharmaceutical distribution business.

The Florida-based drug maker said Monday that its board of directors had approved a plan to revise its business strategy and focus on the development of controlled-release pharmaceuticals and distribution.

The company plans to divest or seek other strategic alternatives for its brand pharmaceutical business and has engaged Banc of America Securities LLC to solicit offers for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.